raises $21M Series A-1 for cancer treatment vaccine, infectious diseases vaccine R&D
Summary
“I have long committed to the research and development of vaccines against cancer and infectious diseases so the people across the globe can lead normal lives,” says Wataru Akahata, CEO and co-founder of VLPT. Wataru Akahata, Ryuji Ueno, and Sachiko Kuno, is a Gaithersburg, MD-based biotech company with a mission to address unmet medical needs worldwide and expand the frontiers of vaccine treatment. In 2002 he earned a PhD for his HIV vaccine studies under supervision of professor Hayami Masanori at the Kyoto University Institute for Virus Research. In addition to his role as the co-founder and CEO of VLP Therapeutics, Inc. in the US and CEO and chief R&D officer of VLP Therapeutics Japan, LLC, Akahata serves as a visiting professor at the Tokyo Institute of Technology and specially appointed associate professor at the Kyoto University Graduate School of Medicine in Japan. • December 27, 2021 | MUFG Bank, Ltd. | press release: “MUFG to Invest in VLP Therapeutics, Inc.“ • December 27, 2021 | Sojitz Corporation | press release: “Sojitz Makes Additional Investment in VLP Therapeutics, Inc., a U.S.